1. Home
  2. SLG vs PBLS Comparison

SLG vs PBLS Comparison

Compare SLG & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SL Green Realty Corp

SLG

SL Green Realty Corp

HOLD

Current Price

$58.17

Market Cap

3.1B

Sector

Real Estate

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$38.90

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLG
PBLS
Founded
1980
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.6B
IPO Year
1997
2026

Fundamental Metrics

Financial Performance
Metric
SLG
PBLS
Price
$58.17
$38.90
Analyst Decision
Buy
Analyst Count
19
0
Target Price
$50.63
N/A
AVG Volume (30 Days)
803.0K
345.6K
Earning Date
04-15-2026
N/A
Dividend Yield
7.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,003,046,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.18
N/A
52 Week Low
$34.77
$25.56
52 Week High
$66.29
$41.49

Technical Indicators

Market Signals
Indicator
SLG
PBLS
Relative Strength Index (RSI) 60.22 59.45
Support Level $43.50 $38.00
Resistance Level N/A $41.49
Average True Range (ATR) 1.62 2.16
MACD -0.03 -0.15
Stochastic Oscillator 66.22 55.44

Price Performance

Historical Comparison
SLG
PBLS

About SLG SL Green Realty Corp

SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 31.4 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: